# The Role of Phosphodiesterase Inhibitors in Incretin Secretion

> **NCT02363335** · PHASE1 · COMPLETED · sponsor: **National Institute on Aging (NIA)** · enrollment: 29 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **OTHER:** Placebo
- **OTHER:** Roflumilast/Sitagliptin
- **OTHER:** Sitagliptin
- **OTHER:** Roflumilast

## Key facts

- **NCT ID:** NCT02363335
- **Lead sponsor:** National Institute on Aging (NIA)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-13
- **Primary completion:** 2016-09-19
- **Final completion:** 2016-09-19
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02363335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02363335, "The Role of Phosphodiesterase Inhibitors in Incretin Secretion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02363335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*